Jan 3, 2021
(June 2019) The Michael J. Fox Foundation, a leading organization in the field of research and treatment of Parkinson's Disease (PD) and related disorders, has awarded QDTI a research grant to develop an ultrasensitive assay for protein biomarkers associated with the Leucine-rich repeat kinase 2 (LRRK2) pathway. The LRRK2 pathway is a rapidly emerging area of PD diagnostic and therapeutic research, but new assays are needed to assist in PD drug development efforts. . QDTI will implement the protein biomarker assay on its novel all-magnetic detection platform.